Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

INTRODUCTION: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Adv Ther
Auteurs principaux: Ramaswamy, Krishnan, Lechpammer, Stanislav, Mardekian, Jack, Huang, Ahong, Schultz, Neil M., Sandin, Rickard, Wang, Li, Baser, Onur, George, Daniel J.
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2020
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467473/
https://ncbi.nlm.nih.gov/pubmed/32112280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01260-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires